GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » EV-to-EBITDA

Sensei Biotherapeutics (HAM:407) EV-to-EBITDA : 1.07 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sensei Biotherapeutics's enterprise value is €-30.18 Mil. Sensei Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-28.15 Mil. Therefore, Sensei Biotherapeutics's EV-to-EBITDA for today is 1.07.

The historical rank and industry rank for Sensei Biotherapeutics's EV-to-EBITDA or its related term are showing as below:

HAM:407' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.85
Current: 1.07

During the past 6 years, the highest EV-to-EBITDA of Sensei Biotherapeutics was 2.85. The lowest was 0.00. And the median was 0.00.

HAM:407's EV-to-EBITDA is ranked better than
78.49% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs HAM:407: 1.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Sensei Biotherapeutics's stock price is €0.702. Sensei Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.117. Therefore, Sensei Biotherapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sensei Biotherapeutics EV-to-EBITDA Historical Data

The historical data trend for Sensei Biotherapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics EV-to-EBITDA Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - -0.91 1.13 1.30

Sensei Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.94 1.20 1.30 0.86

Competitive Comparison of Sensei Biotherapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Sensei Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensei Biotherapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's EV-to-EBITDA falls into.



Sensei Biotherapeutics EV-to-EBITDA Calculation

Sensei Biotherapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-30.177/-28.146
=1.07

Sensei Biotherapeutics's current Enterprise Value is €-30.18 Mil.
Sensei Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sensei Biotherapeutics  (HAM:407) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sensei Biotherapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.702/-1.117
=At Loss

Sensei Biotherapeutics's share price for today is €0.702.
Sensei Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.117.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sensei Biotherapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics (HAM:407) Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics (HAM:407) Headlines

No Headlines